Long-Term Therapy with Bevacizumab in Hereditary Hemorrhagic Telangiectasia

To the Editor: Management of severe epistaxis resulting from hereditary hemorrhagic telangiectasia (HHT) can be invasive, and its effect is not durable in reducing the frequency and severity of bleeding events. Several reports have shown the efficacy of bevacizumab in treating patients with HHT.1–3 We describe the long-term outcome of a patient who received multiple repeat courses of intravenous bevacizumab for severe HHT. The patient, a 62-year-old man with severe HHT-related epistaxis, required blood transfusions and intravenous iron therapy to maintain a baseline hemoglobin level ranging from 5 to 7 g per deciliter. He received four intravenous infusions of . . .